Medical Therapeutics

Caribou Biosciences Inc.

Brief Description

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T cell platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.

...

4D Molecular Therapeutics LLC

Brief Description

4D Molecular Therapeutics is a global leader in gene therapy product research and development using scientific innovation to unlock the full potential of gene therapy for patients with genetic diseases. Their robust discovery platform, termed Directed Vector Evolution, empowers creation of customized gene delivery vehicles (novel AAV vectors) to deliver normal genes to tissues or organs with defective genes. as occurs in genetic diseases. This 4DMT discovery technology was originally developed over 15 years by co-Founder David Schaffer at UC Berkeley.

Inventors David...

EditPep, Inc.

Brief Description

CRISPR therapies enabled by a simple, potent delivery platform. The biotechnology company creates a class of peptides capable of delivering CRISPR enzymes into clinically-relevant and previously untransfectable cell types, enabling clients to get CRISPR therapies.

Founders

Dana Foss, Ross Wilson

Inventors

Ross Wilson, Dana Foss, Alexander Marson, Srishti Sahu, David-Huy Nguyen, John Hunsinger, Daniel Carr

Timeline 2021. Company founded. 2023. Company participated Berkeley SkyDeck accelerator, Batch 16...

Juvena Therapeutics

Brief Description

Juvena Therapeutics is discovering novel protein-based therapeutics that promote tissue regeneration in the elderly and treat various age-related diseases. The company's AI-enabled discovery platform maps the therapeutic potential of secreted proteins, with the goal of accelerating the discovery of treatments that help individuals maintain and even improve their muscle mass and function, which is commonly affected by aging.

The company was born out of CEO and co-founder Hanadie Yousef's research as a PhD student at UC Berkeley, in the laboratories of Drs. David...

Addition Therapeutics

Brief Description

Addition is transforming genetic medicine by developing RNA-only therapeutics that PRINT™ any genetic element at specific safe harbor sites.

Timeline 2021. Company founded Inventors

Kathy Collins, Jeremy John McIntyre, Sarah Madeline Palm, Heather Upton, Briana Nicole Van Treeck. Xiaozhu Zhang

Chiron Corporation

Brief Description

Chiron Corporation was an American biotechnology company engaged in biopharmaceuticals, vaccines and blood testing. Chiron was co-founded in 1981 by UC Berkeley biochemistry professor Edward Penhoet.

Timeline 1981. Company founded 1990. Company Initial Public Offering on NASDAQ under the ticker symbol of CHIR. 2006. Acquired by Novartis Inventors

Henry Chang, Felix Karim, Gerald Rubin, Marc Therrien, David Wassarman

Tularik Inc.

Brief Description

Tularik, Inc. engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company’s drugs include T67, T607, T131, T71, and T487. The T67 is an anti-cancer drug. The T607 would be used for treating gastric cancer and esophageal cancer. The T131 would be used for treating diabetes. The T71 would be used for treating obesity.

Tularik was co-founded in 1991 by UC Berkeley Professor Robert Tjian. Amgen acquired Tularik for $1.3 billion in 2004.

Timeline 1991. Company founded...

Exelixis, Inc.

Brief Description

Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, the company established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. The company developed CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and partnered with leading...

Resvita Biosciences

Brief Description

Resvita Biosciences seeks to restore and maintain the vitality of the skin by properly considering the skin microbiome as part of the human body. A harmless skin probiotic will continuously deliver the therapy that a body would to maintain skin health.

Through synthetic biology and metabolic engineering, the company's goal is to develop a safe and versatile skin microbial platform that can address the causes of skin aging and disease. Resvita Biosciences has a unique patented approach, a rich product pipeline, clear regulatory advantages, and an experienced...

Inapill

Brief Description

Inapill is developing novel therapeutics that tune immune cell metabolism (immunometabolism) to treat diseases caused by immune system overactivation and excessive inflammation.

The company was co-founded by Greg Timblin and Josh Farahzad. CEO Timblin earned his Ph.D. in Molecular & Cell Biology from UC Berkeley in 2014, in the labs of Professors Mark Schlissel and Robert Tjian. He also served as a postdoctoral fellow in Professor Kaoru Saijo’s lab at UC Berkeley, and then in Professor Val Weaver’s lab at UCSF.

Timeline...